BRTX
BioRestorative Therapies, Inc.
There isn't enough reported data to score BRTX yet.
LLY
Eli Lilly and Company
LLY's fundamentals are strong: revenue grew 46% and it turned 23% of its revenue into free cash flow. At 46x earnings, it's trading in line with its usual 48x. Analysts expect that strong growth to continue.
BRTX Fundamentals
| Metric | Status |
|---|---|
| Weak | |
| Weak | |
| Weak | |
| Unavailable |
BRTX's revenue, profitability and cash flow are currently weak. There isn't enough data to rate its balance sheet.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
BRTX PE Valuation
BRTX has no meaningful PE right now: it lost money over the past year.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
BRTX Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong growth | |
| -- | |
| Limited | |
| -- |
Analysts expect BRTX's losses to shrink, with revenue growing.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for LLY, with profitability improving.
BRTX Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q1 2026 | -$21.20 | +$8.20 |
| Q4 2025 | -$31.60 | -$8.40 |
| Q3 2023 | -$82.67 | +$641.93 |
| Q2 2023 | -$95.47 | +$703.33 |
| Q1 2023 | -$105.67 | +$667.53 |
| Q4 2022 | -$102.47 | +$1,443.33 |
| Q3 2022 | -$724.60 | +$175.20 |
| Q2 2022 | -$798.80 | +$1.20 |
LLY has the stronger earnings trend. Trailing diluted EPS is down 172% for BRTX versus LLY up 51%.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY's earnings per share have climbed steadily: $30.81 over the past year, up 51% from the year before, and higher year over year for 11 quarters in a row.
BRTX Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q4 2025 | $34.6K | -71% |
| Q3 2025 | $57.7K | -75% |
| Q2 2025 | $303.3K | +72% |
| Q1 2025 | $100K | -39% |
| Q4 2024 | $119K | -68% |
| Q3 2024 | $233.6K | +661% |
| Q2 2024 | $175.9K | +173% |
| Q1 2024 | $162.6K | +419% |
LLY has the stronger quarterly revenue trend. Revenue is down 71% for BRTX versus up 39% for LLY.
| Quarter | Margin | YoY |
|---|---|---|
| Q4 2025 | -11060% | -8799 points |
| Q3 2025 | -6424% | -5445 points |
| Q2 2025 | -1090% | +313 points |
| Q1 2025 | -4809% | -2282 points |
| Q4 2024 | -2261% | -1405 points |
| Q3 2024 | -979% | +9133 points |
| Q2 2024 | -1403% | +3429 points |
| Q1 2024 | -2527% | +15936 points |
BRTX's operating margin was −11060% last quarter, down 8799 points from the same quarter a year ago.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY's revenue has grown year over year for 14 quarters in a row: $24.4B last quarter, up 39% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY's operating margin was 34% last quarter, down 6.6 points from the same quarter a year ago.
BRTX Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q4 2025 | -$2.5M | -$134.6K |
| Q3 2025 | -$2.9M | -$1.1M |
| Q4 2024 | -$2.4M | -$516.8K |
| Q3 2024 | -$1.8M | -$568.3K |
| Q4 2023 | -$1.8M | -$227.5K |
| Q3 2023 | -$1.2M | +$237.4K |
| Q2 2023 | -$1.2M | +$229.4K |
| Q1 2023 | -$2.4M | -$704.6K |
LLY has the stronger cash trend. Its trailing FCF is up 259% versus its history, compared with BRTX at down 75%.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY generated $19.7B in free cash flow over the past year, up 112% from the year before.
BRTX Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +94% | +431K shares |
| 1 year | +128% | +498K shares |
| 3 years | +387% | +704K shares |
| 5 years | +7286% | +874K shares |
BRTX has 886,387 diluted shares, up 128% from a year ago.
| Quarter | Spent |
|---|---|
| Q1 2026 | — |
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has the edge over BRTX on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
BRTX Net Leverage
BRTX's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY's net debt is about 1.2 years of its operating earnings (EBITDA), about the same as a year ago.
BRTX Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 28.8 | Oversold |
| Stochastic | 5.3 | Oversold |
BRTX's weekly RSI is 29 (oversold) and its Stochastic is 5 (oversold).
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
BRTX PE vs Healthcare Sector
BRTX has no meaningful PE right now: it lost money over the past year.
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
BRTX Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1.77 | 15% below |
| 20 week MA | $3.54 | 58% below |
| 50 week MA | $8.25 | 82% below |
| 100 week MA | $20.7 | 93% below |
| 200 week MA | $33.5 | 96% below |
BRTX is in a downtrend: it's below all five of its weekly moving averages, and 96% below its 200-week average.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY has the edge over BRTX on trend strength, trading above more of its moving averages.
BRTX Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $640.0 | $664.0 | +3.8% |
| 2021 | $664.0 | $96.0 | -86% |
| 2022 | $96.0 | $59.8 | -38% |
| 2023 | $59.8 | $34.8 | -42% |
| 2024 | $34.8 | $31.0 | -11% |
| 2025 | $31.0 | $22.4 | -28% |
| 2026 YTD | $22.4 | $1.50 | -93% |
BRTX has finished five years in a row lower, and it's down 93% so far in 2026.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has the edge over BRTX on returns for 2026, with the stronger performance.